Table 2.
Association between lysophosphatidic acid concentration in vaginal secretions and differential pathological diagnosis in women with a benign or malignant adnexal mass.
| Diagnosis | No. women | LPA (μM) |
|---|---|---|
| Malignant | ||
| Endometroid +/- Clear cell | 11 | 7.9 (1.9–24.3)a |
| Serous | 6 | 9.5 (1.0–16.1)b |
| Mucinous | 3 | 2.6 (1.2–15.2) |
| MMMT | 2 | 1.1 (0.9–1.4) |
| Granulosa | 2 | 9.1 (4.2–14.1) |
| Other | 2 | 4.4 (1.6–7.3) |
| Clear cell | 1 | 1.6 |
| Mixed | 1 | 0.2 |
| Borderline | ||
| Serous | 2 | |
| Mucinous | 2 | |
| Benign | ||
| Cystadenoma | 30 | 1.2 (0.4–6.6) |
| Other cysts | 23 | 2.7 (1.2–21.8) |
| Teratoma | 6 | 1.1 (0.5–2.3) |
| Fibroma | 6 | 2.0 (0.5–4.4) |
| Endometriosis | 3 | 0.3 (0–7.9) |
| Total benign | 68 | 1.5 (0.5–4.3) |
Values are median (25%–75%) μM; Endometrioid +/− Clear cell, endometrioid tumor with and without clear cell components; MMMT, malignant mixed mesoderm tumor (carcinosarcoma); Other, metastatic adrenal, leiomyosarcoma.
ap = 0.0137 vs. benign; bp = 0.1267 vs. benign; cp = 0.1208 vs. benign.